COPD, stage and treatment in a large outpatient clinic
Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exac...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-01-01
|
| Series: | European Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20018525.2017.1267470 |
| _version_ | 1818603505350344704 |
|---|---|
| author | Claire Præst Holm Jakob Holm Annette Nørgaard Nina Godtfredsen |
| author_facet | Claire Præst Holm Jakob Holm Annette Nørgaard Nina Godtfredsen |
| author_sort | Claire Præst Holm |
| collection | DOAJ |
| description | Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exacerbations. Our aim was to describe COPD patient characteristics and compare roflumilast treatment eligible to non-eligible patients. An observational cross-section study was conducted. Patients were included from a large COPD outpatient clinic. Information regarding COPD patient characteristics was registered on a standardized form and lung function was measured. Patients were categorized according to the GOLD classification. Eligibility for roflumilast treatment was assessed and patient characteristics compared between groups. 547 patients were included. Most patients (54%) were in GOLD group D. 62 patients (11.3%) met the criteria for treatment with roflumilast. Among the patients eligible for roflumilast treatment, only 14 patients (22.6%) were receiving treatment. There were no significant differences in FEV1, number of exacerbations, hospitalization due to exacerbation, MRC grade, age, smoking status and medication use between patients receiving roflumilast and not treated eligible patients. Our study documents low use of roflumilast treatment. In view of the established effect of roflumilast we think that this treatment should be considered more consistently as an option among COPD patients fulfilling the criteria for this therapy. |
| first_indexed | 2024-12-16T13:24:14Z |
| format | Article |
| id | doaj.art-5a9aaa3cbbd34fffb7d126b1cd8ba984 |
| institution | Directory Open Access Journal |
| issn | 2001-8525 |
| language | English |
| last_indexed | 2024-12-16T13:24:14Z |
| publishDate | 2017-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | European Clinical Respiratory Journal |
| spelling | doaj.art-5a9aaa3cbbd34fffb7d126b1cd8ba9842022-12-21T22:30:16ZengTaylor & Francis GroupEuropean Clinical Respiratory Journal2001-85252017-01-014110.1080/20018525.2017.12674701267470COPD, stage and treatment in a large outpatient clinicClaire Præst Holm0Jakob Holm1Annette Nørgaard2Nina Godtfredsen3Copenhagen University HospitalCopenhagen University HospitalLunge- og allergiklinikkenCopenhagen University HospitalSome COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exacerbations. Our aim was to describe COPD patient characteristics and compare roflumilast treatment eligible to non-eligible patients. An observational cross-section study was conducted. Patients were included from a large COPD outpatient clinic. Information regarding COPD patient characteristics was registered on a standardized form and lung function was measured. Patients were categorized according to the GOLD classification. Eligibility for roflumilast treatment was assessed and patient characteristics compared between groups. 547 patients were included. Most patients (54%) were in GOLD group D. 62 patients (11.3%) met the criteria for treatment with roflumilast. Among the patients eligible for roflumilast treatment, only 14 patients (22.6%) were receiving treatment. There were no significant differences in FEV1, number of exacerbations, hospitalization due to exacerbation, MRC grade, age, smoking status and medication use between patients receiving roflumilast and not treated eligible patients. Our study documents low use of roflumilast treatment. In view of the established effect of roflumilast we think that this treatment should be considered more consistently as an option among COPD patients fulfilling the criteria for this therapy.http://dx.doi.org/10.1080/20018525.2017.1267470copdexacerbationsroflumilastphosphodiesterase-4 inhibitorgold groupsoutpatientsfrequent exacerbator |
| spellingShingle | Claire Præst Holm Jakob Holm Annette Nørgaard Nina Godtfredsen COPD, stage and treatment in a large outpatient clinic European Clinical Respiratory Journal copd exacerbations roflumilast phosphodiesterase-4 inhibitor gold groups outpatients frequent exacerbator |
| title | COPD, stage and treatment in a large outpatient clinic |
| title_full | COPD, stage and treatment in a large outpatient clinic |
| title_fullStr | COPD, stage and treatment in a large outpatient clinic |
| title_full_unstemmed | COPD, stage and treatment in a large outpatient clinic |
| title_short | COPD, stage and treatment in a large outpatient clinic |
| title_sort | copd stage and treatment in a large outpatient clinic |
| topic | copd exacerbations roflumilast phosphodiesterase-4 inhibitor gold groups outpatients frequent exacerbator |
| url | http://dx.doi.org/10.1080/20018525.2017.1267470 |
| work_keys_str_mv | AT clairepræstholm copdstageandtreatmentinalargeoutpatientclinic AT jakobholm copdstageandtreatmentinalargeoutpatientclinic AT annettenørgaard copdstageandtreatmentinalargeoutpatientclinic AT ninagodtfredsen copdstageandtreatmentinalargeoutpatientclinic |